Outcomes of real-world patients with non-valvular atrial fibrillation on anticoagulants ineligible for Phase III trials of direct oral anticoagulants
Running title: Real-world patients with NVAF
Mayumi Higa1, Takeshi Morimoto2, Masayuki Ikeda3, Shinichiro Ueda1,4,5
1Department of Clinical Research and Management, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
2Department of Clinical Epidemiology, Hyogo Medical University, Hyogo, Japan.
3 Department of Medical Informatics, Kagawa University School of Medicine, Kagawa, Japan.
4 Department of Clinical Pharmacology & Therapeutics, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
5 Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
Correspondence:
Dr Shinichiro Ueda, Department of Clinical Pharmacology & Therapeutics,
University of the Ryukyus Graduate School of Medicine, Okinawa, 903-0215 Japan
Email:blessyou@med.u-ryukyu.ac.jp
ORCID ID https://orcid.org/0000-0001-8133-9361
Phone: +81-98-895-1195
The authors confirm that the Principal Investigator for this paper is Dr Shinichiro Ueda and that he had direct clinical responsibility for patients.
Keywords: non-valvular atrial fibrillation, anticoagulation, Phase III trial, eligibility
Word count: 2469
Table count: 5
Figure count: 2